Market Research Logo

Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Pipeline Review, H2 2016

Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Pipeline Review, H2 2016’, provides in depth analysis on Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2)
  • The report reviews Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) Overview
Therapeutics Development
Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Products under Development by Stage of Development
Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Products under Development by Therapy Area
Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Products under Development by Indication
Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Products under Development by Companies
Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Products under Development by Universities/Institutes
Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Companies Involved in Therapeutics Development
Alkermes Plc
Biomar Microbial Technologies
Cyxone AB
OncBioMune Pharmaceuticals Inc.
Transgene SA
ZIOPHARM Oncology, Inc.
Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Drug Profiles
ALKS-4230 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Anti-PD1 Antibody + TILT-123 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic to Activate IL-2 for Graft Versus Host Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNZ-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chimeric Antigen Receptor T Cell + TILT-123 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IB-08C175 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Prostatac - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T-20K - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TG-4010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TILT-123 + Tumor Infiltrating Lymphocytes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target CD80 and IL-2 for Acute Myeloblastic Leukemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target IL-2 and E7 Protein for Cervical Cancer and Oropharyngeal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Dormant Projects
Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Discontinued Products
Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Featured News & Press Releases
Oct 24, 2016: Immunotherapy Expert Dr. Brian Barnett Joins OncBioMune Scientific Advisory Board
Oct 19, 2016: OncBioMune Receives Notice of Patent Allowance for Novel Cancer Vaccine ProscaVax in Mexico
Sep 26, 2016: OncBioMune CEO Dr. Jonathan Head to Present Abstract on Prostate Cancer Vaccine at Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science Into Survival
Aug 08, 2016: Latest Data From Phase 1 Trial of ProscaVax for Prostate Cancer Reinforces Safety and Benefit of Novel Cancer Vaccine
Jul 20, 2016: Pre-Clinical Research Supports Additional Studies of OncBioMune Technology for Breast Cancer Vaccine
Jul 13, 2016: OncBioMune Submits Protocol to Initiate Phase 2/3 Trial of ProscaVax for Prostate Cancer
Jun 14, 2016: OncBioMune Provides Corporate Update; ASCO Reinforces Market Opportunity for New Prostate Cancer Vaccine as Phase 2 Trial Approaches
Jun 02, 2016: Mexican Regulatory Authorities Supportive of OncBioMunes Phase 2 of ProscaVax for Prostate Cancer
May 25, 2016: Alkermes Announces Initiation of Phase 1 Clinical Study of Immuno-Oncology Drug Candidate ALKS 4230
May 18, 2016: Doctors Voice Optimism About Phase 2 Trial of ProscaVax in Mexico for Prostate Cancer
May 11, 2016: OncBioMune Provides Update on Phase 2 Clinical Trials of ProscaVax for Prostate Cancer
May 04, 2016: OncBioMune Submits Protocol to Principal Investigators for Two Phase 2 Clinical Trials of ProscaVax for Prostate Cancer
Apr 28, 2016: OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax in China
Apr 12, 2016: OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax in Hong Kong
Mar 29, 2016: Multiple sclerosis: plant peptide could prevent onset of the disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Number of Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pipeline by Alkermes Plc, H2 2016
Pipeline by Biomar Microbial Technologies, H2 2016
Pipeline by Cyxone AB, H2 2016
Pipeline by OncBioMune Pharmaceuticals Inc., H2 2016
Pipeline by Transgene SA, H2 2016
Pipeline by ZIOPHARM Oncology, Inc., H2 2016
Dormant Projects, H2 2016
Dormant Projects (Contd..1), H2 2016
Dormant Projects (Contd..2), H2 2016
Discontinued Products, H2 2016
List of Figures
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Top 10 Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Type, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report